The present invention relates to therapeutically active xanthine compound derivatives, corresponding pharmaceutical formulations containing, processes for making or manufacture and the use of the aforementioned compounds in therapy, particularly in the treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.
本发明涉及治疗活性
黄嘌呤化合物衍
生物,相应的制药配方,制造或制造过程以及上述化合物在治疗中的使用,特别是在治疗HM74A受体欠活化导致疾病或激活受体有益的疾病中的治疗。